Special Issue

Barrier Dynamics and Immune Interplay in Brain Aging and Injury

Message from the Guest Editors

We are pleased to announce the launch of a Special Issue that focuses on the lasted advances in research concerning barrier dynamics and immune interplay in brain aging and neurovascular disorders. Aging is the most significant risk factor for numerous neurodegenerative disorders and neurovascular diseases. A hallmark of aging is the development of systemic maladaptive immune responses, both in the periphery and central nervous system (CNS). As the primary interface connecting the periphery and the CNS, the integrity of the blood-brain barrier (BBB) plays a pivotal role in CNS function. Accumulating evidence suggests that systemic immune response and barrier integrity affect brain function. In this Special Issue, we aim to provide the most recent updates on research focused on ameliorating brain dysfunction by targeting barrier dynamics and immune interplay between the periphery and the CNS, in the context of aging, neurodegenerative disorders and neurovascular diseases. We welcome both original and review articles.

Guest Editors

Dr. Hansen Chen

Dr. Congcong Wang

Dr. Xin Wang

Dr. Zongshi Qin

Deadline for manuscript submissions

closed (24 February 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/188117

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

